key: cord-0316691-szsz1n4k
authors: Lim, R.; Cheng, H. L.; Huan, J.; Kongsuphol, P.; DO Shunmuganath, B.; Ming, W. C.; Ng, S. Y.; Gao, X.; Turaga, S. P.; Heussler, S. P.; Somani, J.; Sengupta, S.; Tay, D. M.; McBee, M. E.; Young, B.; MacAry, P. A.; Sikes, H. D.; Preiser, P.
title: Finger stick blood test to assess post vaccination SARS-CoV-2 neutralizing antibody response against variants
date: 2021-11-14
journal: nan
DOI: 10.1101/2021.11.11.21266241
sha: 8b38a145e7b19eb89878ff35d8758f57097b0418
doc_id: 316691
cord_uid: szsz1n4k

There is clinical need for a quantifiable point-of-care (PoC) SARS-CoV-2 neutralizing antibody (nAb) test that is adaptable with the pandemics changing landscape. Here, we present a rapid and semi-quantitative nAb test that uses finger stick or venous blood to assess the nAb response of vaccinated population against wild-type, alpha, beta, gamma, and delta variant receptor binding domains. It captures a clinically relevant range of nAb levels, and effectively differentiates pre-vaccination, post 1st dose and post 2nd dose vaccination samples within 10 minutes. The data observed against alpha, beta, gamma, and delta variants agrees with published results evaluated in established serology tests. Finally, our test revealed a substantial reduction in nAb level for beta, gamma, and delta variants between early BNT162b2 vaccination group (within 3 months) and later vaccination group (post 3 months). This test is highly suited for PoC settings and provides an insightful nAb response in a post-vaccinated population.

Highly transmissible SARS-CoV-2 variants such as B.1.1.7 (alpha) and B.1. 617 We previously developed a rapid paper-based SARS-CoV-2 neutralization assay 93 known as cellulose pulled-down virus neutralization test (cpVNT) that detects SARS-develop a PoC nAb detection test, we improved our cpVNT assay enabling it to be 102 used directly on whole venous or capillary blood including finger stick blood samples. 103

This bypasses the requirement for extensive sample processing or a phlebotomist. 104

Comparison of this modified cpVNT test with established pVNT as well as an ELISA-105 based assay showed high degree of concordance. Importantly, the modified cpVNT 106 To adapt the previous cpVNT for the analysis of whole blood PoC diagnostic samples 114 it was important to change the enzyme/substrate-based reporter system of HRP/TMB 115 as well as the overall assay workflow. The two key modifications introduced are (i) the 116 change to a fluorescent reporter molecule and (ii) sequential incubation steps (Fig. 1A , 117 S1A). For this, we selected Alexa Fluor® 594 as the reporter in consideration of its 118 high quantum yield, excellent photostability, and minimal interference with blood. In 119 addition, to improve the test performance and minimize the non-specific background 120 from whole blood sample, we altered the cpVNT workflow to a two-step incubation, as 121 compared to the one-step incubation reported previously. First, 20 µL of blood sample 122 was mixed with 20 µL of 10 nM RBD-CBD for 3 minutes before adding 40 µL of 5 nM 123 fluorescence labelled human ACE2 (ACE2-AF594) and incubating for additional 5 124 minutes at ambient temperature. Equal amount of the final 80 µL mixture was then 125 applied to the cassette's test and control spot respectively followed by one washing 126 step with 40 µL of PBS for each spot (Fig. 1A & B) . The additional 3 minutes incubation 127 regardless of the level of nAb present in the blood (Fig. 1A , S1 D). A portable 136 fluorescent reader, Atto Testbed produced by Attonics Systems Pte. Ltd., Singapore 137 is customized to allow the detection of fluorescence signal under a PoC setting. The 138 reader excites the fluorophores using LED light. The emitted fluorescent intensity is 139 then detected using a silicon avalanche photodiode and reported as a voltage change 140 in mV unit. This voltage output (mV) can be converted to percentage of blocking 141 according to Equation 1: 142

To evaluate this new test format, we made a series of contrived blood samples by 146 spiking 1, 5, 10, 25, 50 and 100 nM of mouse monoclonal SARS-CoV-2 nAb into a 147 blood prepared with pre-SARS-CoV-2 pandemic plasma and washed red blood cells. 148

The assay demonstrated an IC50 of 3.38 nM nAb using blood as sample matrix ( (ii) non-specific background fluorescence observed from the test when RBD-CBD was 159 absent from the reaction; this value was used to draw a baseline between specific and 160 non-specific signals (see Equation 1 ). The NC value was defined by the median of 161 fluorescence intensity measured from 60 Pre-Vac blood samples in triplicates (Fig  162   S2A ), while the baseline value was the median of triplicate reads from 31 blood 163 samples regardless of vaccination status when RBD-CBD was absent ( Fig S2B) . With 164 this approach, the NC value using two independent batches of ACE2-AF594 resulted 165 in a median fluorescence intensity of 1141 mV (Table S1 and Fig S2A) while the 166 baseline signal had a median intensity value of 230 mV (Fig S2B) . To calculate the 167 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in Once NC and the baseline were established, the nAb levels that block RBD and ACE2 171 interaction were measured in 170 blood samples using modified cpVNT at different 172 stages of vaccination: pre-vaccination (Pre-Vac), 1-2 weeks post 1 st dose (P1 1-2W), 173 3-6 weeks post 1 st dose (P1 3-6W) and 3-16 weeks post 2 nd dose (P2). The Pre-Vac 174 (n=36) group's percent blocking was measured with a median of 1.96%, this number 175 increased to 14.3% in P1 1-2W group (n = 10) and P1 3-4W group at 36.5% (n = 50). 176

Lastly, we observed 89.1% for P2 samples (n=74) (Fig. 2A) . A similar trend was 177 observed when grouping the samples into individuals vaccinated with either 178 BNT162b2 ( Fig 2B) or mRNA-1273 ( Fig 2C) . The negative value of percent blocking 179 observed in the Pre-Vac and P1 1-2W was likely due to viscosity variation among 180 blood samples that could interfere with the binding kinetics of RBD-CBD with cellulose 181 paper in the assay. Overall, the data showed a significant difference between Pre-Vac 182 and P1 3-6W samples across the two different types of vaccines, i.e. BNT162b2 183 (p<0.05) and mRNA-1273 (p<0.001) (Fig 2B & C) . There was also a significant 184 difference (p<0.05) in median percent blocking for P1 3-6W group when compared 185 between BNT162b2 recipients (23.4%, n=30) and mRNA-1273 recipients (51.2%, 186 n=20) ( Fig 2D) . However, in P2 samples, both vaccines show comparable median 187 percent blocking at 84.5% for BNT162b2 and 90.9% for mRNA-1273 recipients ( blocking (Low) in the modified cpVNT ( Fig 3A) . This showed that the test can produce 204 a dose dependent response that captures the clinical range of nAb activity in plasma 205 in under 10 minutes assay time. Since plasma represents approximately 55% of whole 206 blood, the percent blocking test results in plasma samples was expected to be higher 207 than that of whole-blood due to the lack of erythrocytes. To correlate the percent 208 blocking in the WHO standard and reference panel plasma to corresponding whole 209 blood, we analyzed 30 matching samples of blood and plasma in the modified cpVNT. 210

We found that the percent blocking in blood samples is approximately 0.87 times of 211 that in plasma samples assuming the relationship between the two sample types are 212 linear ( Fig 3B) . We observed that the overall median percent blocking in Pre-Vac 213 samples was found below 30% blocking in modified cpVNT using blood as matrix ( Fig  214   2A ). It corresponds to 44 IU/mL neutralizing antibody activity which is close to the 215 estimated protective neutralization against SARS-CoV-2 of approximately of 54 IU/mL 216 by Khoury et al.'s predictive model 12 ( Fig 3B) . Hence, 30% blocking which correlates 217 to 44 IU/mL was set as the cut-off value for the modified cpVNT to compare its 218 performance with other neutralization tests ( Fig 3B) . Our test showed 81.5% 219 sensitivity (CI 61.9-93.7%) and 100% specificity (CI 81.5-100%) when compared with 220 the commercially available sVNT Genscript cPass TM (Fig 3C) . Meanwhile, as 221 compared to the lab based pVNT test, the modified cpVNT showed 100 % sensitivity 222 (CI 47.8 -99.9%) and 66.7% specificity (CI: 38.4 -88.2%) ( Fig 3D) . For reference, the 223 WHO plasma of nAb activity at 1000 IU/mL, 210 IU/mL and 44 IU/mL when performed 224 with sVNT cPass yielded 94 %, 78% and 19% inhibition respectively (Table S3 ). The 225 lower specificity and sensitivity relative to ELISA and pVNT can be attributed to the 226 difference in sample type (whole blood vs plasma/serum) and different assay 227

To ensure that the modified cpVNT is suitable for PoC setting with finger stick blood, 229

we assessed the correlation of nAb detected in venous vs finger-stick blood sample 230 matrix. A total of 46 matched pairs from Pre-Vac, P1 and P2 samples show a high 231 linear correlation between the two blood sample types, with a Pearson r value of 232 0.9758 (p value < 0.001) and an R 2 of 0.9523 ( Fig S2C) . This demonstrates the 233 suitability of our modified cpVNT for PoC deployment, as only 20 µL of finger-stick 234 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint blood samples is necessary to measure the nAb response in 10 minutes. Moreover, 235 the outcomes are comparable to established lab-based neutralization tests. and/or increase ACE2 receptor binding 13 . We found that the binding affinity of alpha, 249 beta, gamma, and delta are higher than that of wildtype (WT), especially gamma that 250 showed a 3 -fold increase (4.3 nM) in binding affinity comparing to wild-type (12.7 nM) 251 consistent with previous report 13,14 (Table 1) . Furthermore, our result supports 252 published data that the N501Y mutation in the alpha, and gamma variants of RBD 253 contributes to the slow off-rate of the complex 15 (Table 1) . Meanwhile T478K appears 254 to promote fast complex formation based on comparison among delta, kappa, epsilon, 255 and a delta plus variant that shared the L452R mutation (Table 1) . We engineered a 256 hypothetical RBD variant containing N501Y, T478K mutation and annotated it as 'AD' 257 (alpha-delta) variant that is speculated to have fast on-rate and slow off-rate with ACE2. 258

This hypothetical variant confirmed our hypothesis where it binds ACE2 with the 259 highest binding affinity (KD of 3 nM) among the 10 variants (Table 1 ). Next, we assess 260 the activity of these RBD-CBD variants on the modified cpVNT with Pre-Vac blood. 261

Although variants with high affinity to ACE2 showed increased fluorescence intensity 262 than WT RBD-CBD in the modified cpVNT assay at the same reagent concentration, 263

ie. alpha (1.8-fold), beta (1.6-fold), gamma (2.1-fold), delta (1.3-fold), the correlation is 264 not direct. As we observed variant RBD-CBDs epsilon and lambda still generate 265 comparable signal as WT despite the lower ACE2 binding affinity, while AD variant 266 showed merely 1.6-fold increase in signal despite binding ACE2 strongly (Fig. S4A) . 267 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint Besides the binding kinetics, the capture rate of RBD-CBD on the cellulose paper and 268 possible avidity of the different RBD-variants on ACE2 could contribute to the effect. was important to evaluate whether our test was able to stratify response in relation to 282 the different vaccines used. The median percent blocking for BNT162b2 recipients 283 against alpha was 78% (p< 0.01) and delta was 89.2% (p = n.s.) as compared to WT 284 (94.8%). (Fig 4B) . The most substantial reductions of nAb response were observed 285 with beta and gamma variants reaching 55.7% and 49.6% blocking respectively 286 among BNT162b2 recipients (Fig 4B) . In the cohort of mRNA-1273 recipients, we 287 observed reduction to 87.5% with beta variant (p<0.0001) and 80.5% with gamma 288 variant (p <0.0001). 289 290 Next, we also examined and compared the percent blocking of nAb in whole-blood 291 samples from participants within three months or greater than three months after 292 completion of vaccination against WT and 4 VOCs RBD-CBD. Only samples from 293

BNT162b2 recipients were available to us for the greater than three months cohort as 294 it was the first vaccine rolled-out in the Singapore national vaccination program. There 295 was a modest drop of nAb percent blocking from 96% to 68% (28%, p<0.0001) 296 observed in WT RBD-CBD and 77.6% to 40.2% (37.4%, p<0.001) in alpha RBD-CBD 297 between the two groups of samples (Fig 4D) . Meanwhile a more substantial reduction 298 was seen in beta (47.8%, p <0.0001), gamma (49.5%, p <0.001) and delta variant 299 (53.5%, p <0.0001) respectively ( Fig 4D) . It is interesting to observe the stark decline 300 of nAb blocking for delta variant in the post 3 months cohort especially when no 301 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint significant difference of nAb response was detected from WT for samples vaccinated 302 within 3 months (Fig 4A) . The modified cpVNT results agree with recent findings where 303

BNT162b2 vaccine induced protection wanes within 4-5 months especially against the 304 delta variant despite earlier findings suggest effective neutralization 19,20 . This 305 demonstrates that this test can be effectively adapted in the event of future VOC 306 emergence to quickly assess vaccinees' responses and even to identify vulnerable 307 individuals for booster shots to prevent breakthrough infections. 308 309

The rapid modified cpVNT can improve our understanding of the relationship between 311 nAb response and RDB/ACE2 interaction, especially in response to emerging and 312 predictive mutants. Given the complex innate and cell mediated immune response 313 against infection and immune-protection development, factors like synergistic 314 mutations and epitope remodelling to prevent nAb recognition are key to a variant's 315 immune escape characteristics 21 . We tested the influence of RBD/ACE2 interaction 316 on nAb blocking with the hypothetical AD variant that carries N501Y T478K mutation. 317

It was found unable to evade vaccine induced nAb inhibition where it shows 91.8% 318 nAb blocking in the modified cpVNT similar to WT RBD-CBD despite its high affinity 319 to ACE2 (Fig S4B) . Since a single T478K mutation did not present compromising effect 320 on the binding of potent neutralizing mAbs previously 22 , we observed that the 321 additional N501Y mutation in AD variant does not affect nAb binding within the 322 modified cpVNT's reaction time (Fig S4B) . In contrast, the beta variant despite 323

showing modest increase in affinity towards ACE2 (KD 9.6 nM) than WT (KD 12.7 nM), 324 exhibited significantly lower nAb percent blocking than WT (Fig. 4A ). As the K417 and 325 E484 sites are known to escape both class 1 and class 2 anti-RBD antibodies 23 , the 326 combined effect of RBD/ACE2 binding and poor nAb recognition generate more 327 pronounced immune escape response. These examples indicate that the modified 328 cpVNT can be used to systematically assess the RBD mutations and improve our 329 understanding of its underlying molecular mechanism versus nAb response. 330

With the emergence of highly transmissible SARS-CoV-2 variants, the durability and 332

persistence of vaccine effectiveness is of major concern. Although nAb response 333 strongly correlates with immune protection 12 , cellular immunity is essential in providing 334 sustained immune protection upon exposure, particularly against severe illness. 335 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint Therefore, both humoral and cellular immune response are required for a complete 336 assessment of SARS-CoV-2 immunity. While standardized methods for rapid 337 assessment of cellular immunity responses are underway 24 , nAb level measurement 338 remains a reliable indicator for immune-protection at PoC level and deems to be critical 339 at this point. It has been estimated that 90% of convalescent plasma/sera's perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint of WT RBD-CBD. In brief, the proteins were subjected to affinity chromatography with 403

Ni-NTA cartridges (Qiagen, 1046323) and size exclusion chromatography with HiLoad 404 16/60 Sephadex 200 (Cytiva) in 20 mM HEPES pH 7.5, 300 mM NaCl, 10% glycerol. 405

The His-MBP tag of RBD-CBD variants were removed by incubation with TEV 406 protease overnight in 1:40 mass ratio at 4°C. The untagged proteins were further 407 purified by reverse affinity chromatography with HisPur-Ni-NTA resin in 20 mM HEPES 408 pH 7.5, 300 mM NaCl, 10 mM Imidazole. Lastly, the purified RBD-CBD variants were 409 concentrated and stored in 20 HEPES pH 7.5, 300 mM NaCl, 10% glycerol and 0.5 410 mM TCEP at -80°C. Once sample was fully absorbed, both test and control spots were washed once with 435 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint 40 µL of PBS pH 7.6. The cassette was then placed in an Atto Testbed for fluorescence 436 measurement. All steps described above were performed at room temperature. 437 Analysis of binding response was performed by Octet Data Analysis software using 468 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint global 1:1 fitting for KD calculation. All experiments were performed using 8-channel 469

Octet RED96e system (Forté Bio) in PBS, 0.2% BSA and 0.05% Tween 20 at 25°C. 470

We applied the same protocol for production of SARS-CoV-2 pseudotyped lentiviral 472 particles and pseudovirus neutralization assay as previously reported 10 3-6W n=50) and post 2 nd dose (n=74). The grey line is the median from each group 653 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint two groups: within three months (n=20) and more than three months (n=37) after 699 complete vaccination. Two-sided Mann Whitney test was performed between the two 700 groups for each variant, WT P < 0.0001, alpha P < 0.001, beta P < 0.0001, gamma P 701 < 0.001, delta P < 0.0001. 702 703 704 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted November 14, 2021. ; https://doi.org/10.1101/2021.11.11.21266241 doi: medRxiv preprint . The grey line is the median from each group while each dot represents the mean from three independent experiments. B. The nAb percent blocking measured in individuals opt for BNT162b2 (n=4 from P1 -1-2W, n=30 from P1 -3-6W, n=40 from P2) or C. mRNA-1273 (P1 -1-2W n=6, P1 -3-6W n=20, P2 n=34). Kruskal-Wallis test with Dunn's multiple comparison was performed between each vaccination status. D. Comparison of nAb percent blocking at P1 3-6W BNT162b2 and P1 3-6W mRNA-1273. Two tailed Mann-Whitney test was performed between the two vaccine brands. The significance values * P < 0.05, ** P < 0.01, ***P < 0.001, ****P < 0.0001. Total samples: Pre-Vac versus P1 -3-6W, P < 0.001; Pre-Vac versus P2, P < 0.0001. BNT162b2: Pre-Vac versus P1 -3-6W, P < 0.05; Pre-Vac versus P2, P < 0.0001. mRNA-1273: Pre-Vac versus P1 -3-6W, P < 0.001; Pre-Vac versus P2, P < 0.0001. E. Twenty-two individual samples percent blocking mapped over pre and post vaccination period comparing between two types of vaccines, BNT162b2 n=12, mRNA 1273 n=10. The window period between first and second dose of vaccination ranged from 4 to 6 weeks depending on individual's choice.

Total dose (P2) phase using modified cpVNT gave Pearson r, 0.908. The percent blocking for cpVNT with blood samples that correspond to 1000 IU/mL, 220 IU/mL and 44 IU/mL are determined by assuming a linear correlation between the two sample types (see accompanying table). C. Comparison of percent blocking measured in the modified cpVNT with percent inhibition of sVNT (cPass TM ) in 45 matching Pre-Vac, P1 and P2 venous blood and plasma samples. The sensitivity was calculated as 81.5% (CI: 61.9-93.7%), and specificity is 100% (CI: 81.5-100%) when both cpVNT and sVNT's (cPass TM ) threshold were set at 30% blocking. D. Comparison between cpVNT and pseudovirus neutralization test (pVNT) with 20 individuals' sample. The pVNT was performed with plasma in 1:80 dilution. The sensitivity is 100% (CI: 47.8-99.9%) and specificity is 66.7% (CI: 38.4-88.2%) with 30% blocking as a threshold for cpVNT while 50% neutralization for pVNT. All experiments were performed in triplicates. 

Assessment of nAb response to variants of concern depending on vaccine brand or time post vaccination with our modified cpVNT. A. Whole blood samples (n=39) from participants who completed vaccination within three months were tested with wildtype (WT) RBD-CBD and variant RBD-CBD. Friedman test with multiple comparison was performed comparing the variants against WT, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. WT versus alpha, P < 0.01. ; WT versus beta, P < 0.0001 ; WT versus gamma, P < 0.0001; WT versus delta, n.s. B. The percent blocking of nAb measured from 20 P2 samples of BNT162b2 recipients (≤ 3 months) when tested with RBD-CBD variants C. Similarly, percent nAb blocking of 19 P2 samples (≤ 3 months) from mRNA-1273 recipients tested with the RBD-CBD variants. D. The nAb response in BNT16b2 recipients against WT and RBD-CBD variants when comparing two groups: within three months (n=20) and more than three months (n=37) after complete vaccination. Two-sided Mann Whitney test was performed between the two groups for each variant, WT P < 0.0001, alpha P < 0.001, beta P < 0.0001, gamma P < 0.001, delta P < 0.0001.

A. B.

C. 

Covid-19 Breakthrough Infections in

Vaccinated Health Care Workers

COVID vaccine boosters: the most important questions

Three Doses 547 of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Effect of Delta on viral burden and 602 vaccine effectiveness against new SARS-CoV-2 infections in the UK

SARS-CoV-2 variants, spike 605 mutations and immune escape

Reduced neutralization of SARS-CoV-2

.617 by vaccine and convalescent serum

Mapping mutations to the SARS-CoV-611 2 RBD that escape binding by different classes of antibodies

Rapid determination of the wide dynamic 614 range of SARS-CoV-2 Spike T cell responses in whole blood of vaccinated and 615 naturally infected

Mapping Neutralizing

Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by

Convergent antibody responses to

SARS-CoV-2 in convalescent individuals

A human neutralizing antibody targets the 624 receptor-binding site of SARS-CoV-2

Neutralization of while each dot represents the mean from three independent experiments. B. The nAb 654 percent blocking measured in individuals opt for BNT162b2 (n=4 from P1 -1-2W, n=30 655 from P1 -3-6W, n=40 from P2) or C. mRNA-1273

Kruskal-Wallis test with Dunn's multiple comparison was performed 657 between each vaccination status. D. Comparison of nAb percent blocking at

BNT162b2 and P1 3-6W mRNA-1273. Two tailed Mann-Whitney test was performed 659 between the two vaccine brands

Total samples: Pre-Vac versus P1 -3-6W

BNT162b2: Pre-Vac versus P1 -3-6W, P < 0.05; Pre-Vac 662 versus P2, P < 0.0001. mRNA-1273: Pre-Vac versus P1 -3-6W, P < 0.001; Pre-Vac 663 versus P2, P < 0.0001. E. Twenty-two individual samples percent blocking mapped 664 over pre and post vaccination period comparing between two types of vaccines

BNT162b2 n=12, mRNA 1273 n=10. The window period between first and second 666 dose of vaccination ranged from 4 to 6 weeks depending on individual's choice

Comparison of modified cpVNT with international standards and 669 established serology tests. A. The performance of the First WHO International 670 standard Anti-SARS-CoV-2

The correlation 672 of percent blocking measured from 30 matching plasma and blood samples at pre 673 vaccination (Pre-Vac), post 1 st dose (P1) and post 2 nd dose (P2) phase using modified 674 cpVNT gave Pearson r, 0.908. The percent blocking for cpVNT with blood samples 675 that correspond to 1000 IU/mL, 220 IU/mL and 44 IU/mL are determined by assuming 676

Comparison of percent blocking measured in the modified cpVNT with percent 678 inhibition of sVNT (cPass TM ) in 45 matching Pre-Vac, P1 and P2 venous blood and 679